Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth : Market Research Report

Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth

Published by: Datamonitor

Published: Jul. 18, 2008 - 259 Pages

CHAPTER 1 EXECUTIVE SUMMARY: Strategic scoping and focus; Datamonitor insight into the cytotoxic therapy cancer brands market; Related reports; Upcoming reports
CHAPTER 2 MARKET DEFINITION: Cytotoxic therapies by ATC class; L1A - Alkylating agents; L1B - Antimetabolites; L1C - Vinca alkaloids and other plant-derived products; L1D - Antineoplastic antibiotics; L1X2 - Platinum compounds; Report classification of cytotoxic therapies; Antimetabolites; Mitotic inhibitors; DNA-interactive agents; Topoisomerase poisons; Non-covalent DNA binding drugs; Covalent DNA binding drugs - Alkylating agents
CHAPTER 3 MARKET OVERVIEW AND FORECASTS: Seven major markets; Current market assessment; Sales by class; Sales by brand; Sales by country; Future market assessment; Sales by class; Sales by brand; Sales by country; Opportunities and threats; US; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Japan; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; 5EU; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; France; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Germany; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Italy; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Spain; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; UK; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Rest of World snapshot; Current market assessment; Global cytotoxics market; Global antimetabolites market; Global mitotic inhibitors market; Global DNA-interactive agents market
CHAPTER 4 BRAND DYNAMICS: Brand analysis by class; Mitotic inhibitor brands are the smallest class, representing 16% cytotoxic therapies; Brand analysis by indication; Taxotere and TS-1 are the leading cytotoxic therapy cancer brands in terms of number of approved indications; Breast cancer is the indication with the most approved cytotoxic therapy cancer brands; Brand analysis by company; Sanofi-Aventis has the highest number of cytotoxic therapy cancer brands, although patent expiries are looming; Sanofi-Aventis; Taiho; Johnson & Johnson; Brand analysis by event; Abraxane will experience the greatest number of forecast events across the seven major markets; Brand analysis by sales growth; All cytotoxic drug classes show positive sales growth to 2017; Sales growth of antimetabolite brands; Sales growth of DNA-interactive agent brands; Sales growth of mitotic inhibitor brands; Brand versus generic market snapshot; Seven major markets; Generics - higher volume, lower value; Brands - lower volume, higher value; US; Japan; 5EU; France; Germany; Italy; Spain; UK
CHAPTER 5 BRAND PROFILES AND FORECASTS: Abraxane; Brand profile; Brand forecast events; Brand forecast to 2017; Next generation taxane set to enter the EU markets; Alimta; Brand profile; Brand forecast events; Brand forecast to 2017; Line extensions and horizontal expansion will boost Alimta’s sales over the forecast period; Arranon; Brand profile; Brand forecast events; Brand forecast to 2017; Calsed; Brand profile; Brand forecast events; Brand forecast to 2017; Camptosar; Brand profile; Brand forecast events; Brand forecast to 2017; Increased generic competition decreases sales across the seven major markets; Clolar/Evoltra; Brand profile; Brand forecast events; Brand forecast to 2017; Dacogen; Brand profile; Brand forecast events; Brand forecast to 2017; Anticipated high uptake set to make Dacogen a leading cytotoxic therapy cancer brand; Doxil; Brand profile; Brand forecast events; Brand forecast to 2017; Ellence; Brand profile; Brand forecast events; Brand forecast to 2017; Eloxatin; Brand profile; Brand forecast events; Brand forecast to 2017; Top-seller likely to face strong generic competition; Furtulon; Brand profile; Brand forecast events; Brand forecast to 2017; Gemzar; Brand profile; Brand forecast events; Brand forecast to 2017; Blockbuster sales set to be dented by generic entry; Gliadel; Brand profile; Brand forecast events; Brand forecast to 2017; Hycamtin; Brand profile; Brand forecast events; Brand forecast to 2017; Ixempra; Brand profile; Brand forecast events; Brand forecast to 2017; Launch in big indication presents opportunity for novel mitotic inhibitor; Taxol; Brand profile; Brand forecast events; Brand forecast to 2017; Taxotere; Brand profile; Brand forecast events; Brand forecast to 2017; Approval in new indications and extensive use in major tumor types means blockbuster status will be maintained; Temodar; Brand profile; Brand forecast events; Brand forecast to 2017; Tomudex; Brand profile; Brand forecast events; Brand forecast to 2017; Treanda; Brand profile; Brand forecast events; Brand forecast to 2017; TS-1; Brand profile; Brand forecast events; Brand forecast to 2017; UFT; Brand profile; Brand forecast events; Brand forecast to 2017; Vidaza; Brand profile; Brand forecast events; Brand forecast to 2017; Entry into new markets will help boost sales to blockbuster status; Xeloda; Brand profile; Brand forecast events; Brand forecast to 2017; New indications and line extensions will ensure increasing sales; Yondelis; Brand profile; Brand forecast events; Brand forecast to 2017
APPENDIX A - MARKET ASSUMPTIONS: Country-specific assumptions and events; Effect of Medicare Modernization Act in the US; Biennial price cuts in Japan; Generic erosion assumptions; Data definitions, limitations and assumptions; Standard units; Japanese market data; Derivation of sales forecasts and pricing trends; Forecasts; Forecast methodology
APPENDIX B: Bibliography; Journals; Websites; List of figures; Abbreviations; Report methodology; About Datamonitor; About Datamonitor Healthcare; Disclaimer

Abstract

Introduction

Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.

Scope

Analysis of the performance of each of the cytotoxic therapy cancer brands in the seven major markets, forecast to 2017
Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rate
Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
Quantification of the market size of the cytotoxic therapy cancer brands in the seven major pharmaceutical markets with the rest of world markets

Highlights

The cytotoxic therapy cancer brands market is currently worth just over $10 billion and is forecast to grow to sales of almost $15 billion. The launch of the antimetabolite brands, Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitadine; Celgene) in the EU and Japanese markets contributes to this growth.

As a class, DNA-interactive cytotoxic therapy cancer brands contributed the highest proportion of sales in 2007 with $4.3 billion. This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to overtake.

Twenty four companies are involved in the development of currently approved cytotoxic therapy cancer brands, over half of which have more than one cytotoxic brand on the market. Sanofi-Aventis leads with four out of the 25 cytotoxic brands marketed, which made a collective $4,176m for the company in the seven major markets in 2007.

Reasons to Purchase

Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2007 to 2017
Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot

Please note: This is delivered as a Zip file.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth

Table of Contents

Abstract